



Can We Use Nonophthalmic Drug in Ophthalmology? Nonophthalmic Drug potential for ophthalmology

Marianne Shahsuvaryan

Yerevan State Medical University, Armenia

E-mail: mar_shah@hotmail.com

ABSTRACT

Progress in ophthalmology is accompanying with nonophthalmic drug use. Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux across cell membranes and affect various intracellular signaling processes, have been long and widely used to treat essential hypertension and certain types of cardiac diseases such as angina pectoris. Among five subtypes of calcium channels, only specific agents for L-type calcium channels have been used as therapeutics.

There are potentially multiple biological bases for the protective effect of calcium channel blockers on eye structures. The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that calcium channel blockers may be useful in the prevention and the treatment of different eye diseases.

Key words: calcium channel blockers, glaucoma, retinal degeneration, ocular inflammation, neuroprotective effect, antioxidative action.

Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux across cell membranes and affect various intracellular signaling processes, have been long and widely used to treat essential hypertension and certain types of cardiac diseases such as angina pectoris. Among five subtypes of calcium channels, only specific agents for L-type calcium channels have been used as therapeutics. Calcium antagonists induce vasodilatation at smooth muscle cells and are neuroprotective through their intracellular decrease of K^+ .

Calcium channel blockers generally dilate isolated ocular vessels and increase ocular blood flow in experimental animals, healthy humans, patients with open-angle glaucoma [1-3] and in patients who have vascular diseases in which considerable vascular tone is present. As well, contrast sensitivity in patients with normal tension glaucoma was found ameliorated by calcium channel inhibition [4,5]. Neuroprotective effect of calcium channel blockers against retinal ganglion cell damage under hypoxia was shown by Yamada *et al.* [6], and also by Garcia-Campos *et al.* [7]. Apoptosis, genetically programmed mechanism of cell death in which the cell activates a specific set of instructions that lead to the deconstruction of the cell from within, is now understood as a final common pathway for retinitis pigmentosa. Retinitis pigmentosa is an inherited retinal degeneration characterized by nyctalopia, ring scotoma, and bone-spicule pigmentation of the retina. Apoptosis can thus be considered as a therapeutic target for retinitis pigmentosa [8,9].

The general consensus is that intracellular concentrations of calcium ion are increased in apoptosis [10-15].

These findings suggest that calcium channel blockers may potentially inhibit ganglion cells and photoreceptor apoptosis in glaucoma and retinitis pigmentosa respectively [3,16].

There are potentially multiple biological bases for the protective effect of calcium channel blockers on eye structures, as was shown above.

The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that calcium channel blockers may be useful in the prevention and the treatment of different eye diseases.

DILTIAZEM

Frasson *et al.*, [17] (first reported the effects of D-cis- diltiazem, a benzothiazepin calcium channel antagonist which blocks both cyclic-nucleotid-gated cation channels (CNGC) and voltage-gated calcium channels (VGCC) on photoreceptor protection in rd1 mice, several investigators have reported positive and negative effects of calcium channel blockers on animal models of retinitis pigmentosa [13, 18-24].

The intracellular concentration of calcium ions is subsequently elevated, leading to photoreceptor apoptosis [17]. Sanges *et al.* [13] demonstrated that systemic administration of D-cis-diltiazem reduced intracellular concentrations of calcium, downregulating calpains and photoreceptor apoptosis in rd1 mice. Direct inhibitory effects of D-cis-diltiazem on L-type VGCC have been reported by Hart *et al.* [21], and D-cis-diltiazem effectively blocks photoreceptor light damage in mouse models by inhibiting photoreceptor apoptosis [24]. In contrast, L-cis isomer inhibits L-type VGCC similarly to D-cis isomer [25].

The difference in action between D-cis and L-cis-diltiazem on photoreceptor apoptosis suggests that CNGC might also be important for photoreceptor neuroprotection [17]. Despite these studies, however, Takano *et al.* [23] and Pawlyk *et al.* [26] found no rescue effects of D-cis-diltiazem on retinal degeneration in rd1 mice, and Bush *et al.* [18] also reported that D-cis-diltiazem was ineffective for photoreceptor rescue in rhodopsin P23H transgenic rats. The effects of diltiazem on animal models of retinal degeneration remain controversial.

Pasantes-Morales *et al.* [27] in human study reported that a combination of D-cis-diltiazem, taurin, and vitamin E has beneficial effects on the visual field progression, although the study did not clarify whether diltiazem alone demonstrated beneficial effects.

Otori *et al.* [28] evaluated the effect of diltiazem on inhibition of glutamate-induced apoptotic retinal ganglion cells death and concluded that application of diltiazem do not appear to reduce apoptosis.

Investigating the pharmacokinetics of diltiazem after subconjunctival and topical administration in rabbits and effect on wound healing after the creation of conjunctival flaps, Oruc *et al.* [29] have found that topical and subconjunctival diltiazem successfully penetrated the aqueous humor, but did not appear to affect wound healing.

Based on antioxidative action of calcium channel blockers, which have recently been shown, another therapeutic target is ocular inflammation. Animal study of intraperitoneal injections of either nilvadipine, diltiazem, or vehicle have not found a beneficial inhibitory effect of diltiazem on the pathogenesis of ocular inflammation through the suppression of inflammation-related molecules [30].

NIMODIPINE

Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier due to its high lipid solubility. Its primary action is to reduce the number of open calcium channels in cell membranes, thus restricting influx of calcium ions into cells.

Several clinical trials have unequivocally shown that nimodipine is capable of preventing neurological deficits secondary to aneurysmal subarachnoid haemorrhage. The results of the VENUS (Very Early Nimodipine Use in Stroke) study do not support the concept that early nimodipine exerts a beneficial effect in stroke patients [31]. On the other hand oral nimodipine showed an enhanced acute reperfusion if applied within 12 hours of onset of acute stroke [6,31,32]. Yamada *et al.*, [6] in experimental in vitro model revealed that nimodipine have a direct neuroprotective effect against retinal ganglion cells damage related to hypoxia.

Michelson *et al.*, [33] have evaluated the impact of nimodipine on retinal blood flow in double-blind, two-way, crossover study of healthy subjects and found that orally administered at a dosage of 30 mg three times a day nimodipine significantly increases retinal perfusion in healthy subjects. Based on experimental findings Shahsuvaryan [34] investigated the efficacy of nimodipine in the prospective comparative clinical interventional study of patients with nonarteritic anterior and posterior optic neuropathy. The author stated that increase in visual acuity was higher in the posterior ischemic neuropathy subgroup than in the anterior ischemic subgroup. Visual field testing during the follow-up also revealed positive transformation of visual field defects size and location, which correlated to visual acuity changes. These encouraging findings need to be confirmed by double-blind study.

Nimodipine has also been shown to significantly inhibit the growth of new vessels in experimental rat model of retinopathy of prematurity [35]. Vascular endothelial growth factor (VEGF) can induce cell proliferation by activating the calcium channel in cell membrane through the influx of calcium increased. Another animal study [36] also have found a beneficial inhibitory effect of nimodipine on proliferative retinopathy by blocking the influx of calcium and expression of VEGF.

The impact of nimodipine on ocular circulation in normal tension glaucoma have been evaluated in many clinical studies.

Piltz *et al.*, [37] have described a performance-corrected improvement in visual field deviation and contrast sensitivity in patients with normal tension glaucoma (NTG) and in control subjects in a prospective, placebo-controlled double-masked study after oral administration of nimodipine (30 mg twice a day). Other authors [38] also stated that a single dose of 30mg nimodipine normalizes the significantly reduced retinal blood flow in NTG patients with clinical signs of vasospastic hyperactivity. Luksch *et al.*, [1] have examined the impact of 60 mg nimodipine in NTG patients 2 hours after oral administration. Results disclosed that nimodipine increased the blood flow of the optic nerve head by 18% and improved color-contrast sensitivity.

Thus, nimodipine is potentially useful calcium channel blocker for eye disorders treatment due to its high lipid solubility and ability to cross the blood-brain barrier.

NILVADIPINE

Recent experimental evidences suggest that Nilvadipine appear to have beneficial effects on different ocular structures. Ogata *et al.*, [39] have evaluated the effects of nilvadipine on retinal blood flow and concluded that this agent may directly and selectively increase retinal tissue blood flow, while having only minimal effect on systemic circulation including arterial blood pressure. Another experimental study conducted by Uemura and Mizota [40] have also advocated the use of nilvadipine for the treatment of glaucoma or other retinal diseases that have some relation to apoptosis, based on claims that nilvadipine has high permeability to retina and neuroprotective effect to retinal cells. Otori *et al.*, [28] in the experimental study of different calcium channel blockers protective effect against glutamate neurotoxicity in purified retinal ganglion cells has found that nilvadipine significantly reduce glutamate-induced apoptosis.

Systemic administration of nilvadipine has been shown to be effective for protecting photoreceptors in royal college surgeons rats [20], rd1 mice [23], and heterozygous rd2 (rds) mice [24].

In addition to direct effects of calcium channel blockers on intracellular concentrations of calcium ion in photoreceptor cells, other indirect effects are expected such as increased expression of fibroblast growth factor (FGF) 2 [23] and ciliary neurotrophic factor (CNTF) in the retina [24], and increased choroidal blood flow [2].

In the latest animal study of intraperitoneal injections of nilvadipine Ishida *et al.*, [30] have found a beneficial inhibitory effect of this drug on the pathogenesis of ocular inflammation through the suppression of inflammation-related molecules.

Several clinical trials have shown the effectiveness of nilvadipine in retinitis pigmentosa and glaucoma. Ohguro [41] reported the photoreceptor rescue effects of nilvadipine in a small patient group. Nakazawa *et al.*, [16] expanded his nilvadipine study for RP patients to confirm the results. Although both treated and control groups are still small, authors results have shown significant retardation of the mean deviation (MD) slope as calculated by the central visual field (Humphry Visual Field Analyzer, 10-2 Program) after a mean of 48 months of observation.

As these pilot studies are small-sized and cannot completely exclude possible biases, a large-scale, randomized, multicenter human trial of calcium channel blockers is required in order to evaluate their efficacy as therapeutic agents for retinitis pigmentosa.

The potential beneficial impact of nilvadipine on ocular circulation in normal tension glaucoma has been evaluated in different clinical studies.

Yamamoto *et al.*, [42], Tomita *et al.*, [43], Niwa *et al.*, [44] have found that nilvadipine reduces vascular resistance in distal retrobulbar arteries and significantly increases velocity in the central retinal artery in patients with normal tension glaucoma.

Tomita *et al.*, [43] also stated that reduced orbital vascular resistance after a 4-week treatment with 2 mg oral nilvadipine consequently increases the optic disc blood flow.

Koseki *et al.*, [2] conducted a randomized, placebo-controlled, double-masked, single-center 3-year study of nilvadipine on visual field and ocular circulation in glaucoma with low-normal pressure. No topical ocular hypotensive drugs were prescribed.

The authors concluded that nilvadipine (2 mg twice daily) slightly slowed the visual field progression and maintained the optic disc rim, and the posterior choroidal circulation increased over 3 years in patients with open-angle glaucoma with low-normal intraocular pressure. The results of this study add to the growing body of evidence that nilvadipine may be useful for neuroprotection in glaucoma.

Thus, nilvadipine is potentially useful calcium channel blocker for eye disorders treatment due to its hydrophobic nature with high permeability to the central nervous system, including the retina and the highest antioxidant potency among calcium channel blockers.

OTHER CALCIUM CHANNEL BLOCKERS

The experimental study conducted by Oku *et al.*, [45] evaluated the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits and have advocated iganidipine eyedrops for the treatment of ischemic retinal and optic nerve disorders for the maintenance of visual function.

The latest experimental study [46] evaluated a neuroprotective effect of another new calcium channel blocker – lomerizine. The authors stated that lomerizine alleviates secondary degeneration of retinal ganglion cells induced by an optic nerve crush injury in the rat, presumably by improving the impaired axoplasmic flow. Tamaki *et al.*, [47] also investigated the effects of lomerizine on the ocular tissue circulation in rabbits and on the circulation in the optic nerve head and choroid in healthy volunteers and have found that lomerizine increases blood velocity, and probably blood flow, in the optic nerve head and retina in rabbits, and it also increases blood velocity in the optic nerve head in healthy humans, without significantly altering blood pressure or heart rate.

CONCLUSION

In conclusion, there are potentially multiple biological bases for the therapeutic effect of calcium channel blockers in eye diseases. Taken into account that not all calcium channel blockers are equally effective, the challenge for future laboratory research will be to determine the best type and dosage of calcium channel blockers and also to determine which processes are modulated by these drugs in vivo and therefore are primarily responsible for the apparent beneficial effects observed in the previous studies.

Clearly, further observational studies cannot adequately address many unanswered questions. It is time to conduct a randomized controlled trial to provide direct evidence of the effectiveness of specific type nonophthalmic drug - calcium channel blocker in different eye diseases.

REFERENCES

1. Luksch A, Rainer G, Koyuncu D, Ehrlich P, Maca T, Gschwandtner ME, Vass C, Schmetterer L (2005). Effect of nimodipine on ocular blood flow and color contrast sensitivity in patients with normal tension glaucoma. *Br.J.Ophthalmol.* 89:21-25.
2. Koseki N, Araie M, Tomidokoro A (2008). A placebo-controlled 3-year study of a calcium channel blocker on visual field and ocular circulation in glaucoma with low-normal pressure. *Ophthalmology.* 115(11):2049-2057.
3. Araie M and Yamaya C (2011). Use of calcium channel blockers for glaucoma. *Prog Ret Eye Res.* 30:54-71.
4. Yu DY, Cringle S, Valter K, Walsh N, Lee D, and Stone J (2004). Photoreceptor death, trophic factor expression, retinal oxygen status, and photoreceptor function in the P23H rat. *Investigative Ophthalmology and Visual Science.* 45(6):2013-2019.
5. Boehm AG, Breidenbach KA, Pillunat LE, Bernd AS, Mueller MF, Koeller AH(2003). Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers. *Graefes Arch Clin Exp Ophthalmol.* 241:24-38.
6. Yamada H, Chen YN, Aihara M, Araie M (2006). Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. *Brain Res.* 1071(1):75-80.
7. García-Campos J, Villena A, Díaz F, Vidal L, Moreno M, Pérez de Vargas I (2007). Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. *Histol Histopathol.* 22(12):1399-1411.
8. Doonan F and Cotter TG (2004). Apoptosis: a potential therapeutic target for retinal degenerations. *Current Neurovascular Research.* 1(1):41-53.
9. Cottet S and Schorderet DF(2009). Mechanisms of Apoptosis in retinitis pigmentosa. *Current Molecular Medicine.* 9(3):375-383.
10. Nicotera P and Orrenius S (1998). The role of calcium in apoptosis. *Cell Calcium.* 23(2-3):173-180.
11. Fox DA, Poblenz AT and He L (1999). Calcium overload triggers rod photoreceptor apoptotic cell death in chemical-induced and inherited retinal degenerations. *Annals of the New York Academy of Science.* 893:282-285.
12. Delyfer MN, Leveillard T, Mohand-Said S, Hicks D, Picaud S, Sahel A (2004). Inherited retinal degenerations: therapeutic prospects. *Biology of the Cell.* 96(4):261-269.
13. Sanges D, Comitato A, Tammaro R, Marigo V (2006). Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. *Proceedings of the National Academy of Sciences of the United States of America.* 103(46):17366-17371.
14. Paquet-Durand F, Johnson L, Ekstrom P (2007). Calpain activity in retinal degeneration. *Journal of Neuroscience Research.* 85(4):693-702.

15. Read DS, McCall MA, and Gregg RG (2002). Absence of voltage-dependent calcium channels delays photoreceptor degeneration in rd mice. *Experimental Eye Research*. 75(4):415-420.
16. Nakazawa M, Ohguro H, Takeuchi K, Miyagawa Y, Ito T, Metoki T (2011). Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. *Ophthalmologica*. 225(2):120-126.
17. Frasson M, Sahel JA, Fabre M, Simonutti M, Dreyfus H, Picaud S (1999). Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. *Nature*.
18. Bush RA, Kononen L, Machida S, Sieving PA (2000). The effect of calcium channel blocker diltiazem on photoreceptor degeneration in the rhodopsin Pro23His rat. *Investigative Ophthalmology and Visual Science*. 41(9):2697-2701.
19. Pearce-Kelling SE, Aleman TS, Nickle A (2001). Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of pigmentosa. *Molecular Vision*. 7:42-47.
20. Yamazaki H, Ohguro H, Maeda T, Maruyama I, Takano Y, Metoki T, Nakazawa M, Sawada H, Dezawa M (2002). Preservation of retinal morphology and functions in Royal College Surgeons rat by nilvadipine, a Ca²⁺ Antagonist. *Investigative Ophthalmology and Visual Science*. 43(4):919-926.
21. Hart J, Wilkinson MF, Kelly MEM, Barnes S (2003). Inhibitory action of diltiazem on voltage-gated calcium channels in cone photoreceptors. *Experimental Eye Research*. 76(5):597-604.
22. Sato M, Ohguro H, Ohguro I, Mamiya K, Takano Y, Yamazaki H, Metoki T, Miyagawa Y, Ishikawa F, Nakazawa M (2003). Study of pharmacological effects of nilvadipine on RCS rat retinal degeneration by microarray analysis. *Biochemical and Biophysical Research Communications*. 306(4):826-831.
23. Takano Y, Ohguro H, Dezawa M, Ishikawa H, Yamazaki H, Ohguro I, Mamiya K, Metoki T, Ishikawa F, Nakazawa M (2004). Study of drug effects of calcium channel blockers on retinal degeneration of rd mouse. *Biochemical and Biophysical Research Communications*. 313(4):1015-1022.
24. Takeuchi K, Nakazawa M, Mizukoshi S (2008). Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse. *Experimental Eye Research*. 86(1):60-69.
25. Cia D, Bordais A, Varela C, Forster V, Sahel JA, Rendon A, Picaud S (2005). Voltage-gated channels and calcium homeostasis in mammalian rod photoreceptors. *Journal of Neurophysiology*. 93(3):1468-1475.
26. Pawlyk BS, Li T, Scimeca MS, Sandberg MA, Berson EL (2002). Absence of photoreceptor rescue with KD-cis-diltiazem in the rd mouse. *Investigative Ophthalmology and Visual Science*. 43(6):1912-1915.
27. Pasantés-Morales H, Quiroz H and Quesada O (2002). Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. *Metabolic Brain Disease*. 17(3):183-197.
28. Otori Y, Kusaka S, Kawasaki A, Morimura H, Miki A, Tano Y (2003). Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells. *Brain Res*. 31;961(2):213-219.
29. Oruç S, Orhan D, Orhan M, Irkeç M, Başı N, Barun S, Bozkurt A (2000). The pharmacokinetics and effects of diltiazem in rabbits. *Eur J Ophthalmol*. 10(1):46-50.
30. Ishida S, Koto T, Nagai N, Oike Y (2010). Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. *Jpn J Ophthalmol*. 54(6):594-601.
31. Horn J, de Haan RJ, Vermeulen M (2001). Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. *Stroke*. 32:461-465.
32. Infeld B, Davis SM, Donnan GA (1999). Nimodipine and perfusion changes after stroke. *Stroke*. 30:1417-1423.
33. Michelson G, Wärntges S, Leidig S, Lötsch J, Geisslinger G (2006). Nimodipine plasma concentration and retinal blood flow in healthy subjects. *Invest Ophthalmol Vis Sci*. 47(8):3479-86.
34. Shahsuvaryan ML (2008). Neuroprotective therapy in ischemic optic neuropathy. 7th International Symposium on Ocular Pharmacology and Therapeutics. Budapest, Hungary, A60.
35. Juarez CP, Muino JC, Guglielmone H, Sambuelli R, Echenique JR, Hernandez M, Luna JD (2000). Experimental retinopathy of prematurity: angiostatic inhibition by nimodipine, ginkgo-biloba, and dipyridamole, and response to different growth factors. *Eur J Ophthalmol*. 10(1):51-59
36. Kong Y, Han LR, Peng YS, Deng DY (2004). Experimental study of nimodipine and vascular endothelial growth factor in proliferative retinopathy. *Zhonghua Yan Ke Za Zhi*. 40(5):226-330
37. Piltz JR, Bose S, Lanchoney D (1998). The effect of nimodipine, a centrally active calcium antagonist, on visual function and muscular blood flow in patients with normal-tension glaucoma and control subjects. *J Glaucoma*. 7(5):336-342.
38. Michalk F, Michelson G, Harazny J, Werner U, Daniel WG, Werner D (2004). Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. *J Glaucoma*. 13:158-162.
39. Ogata Y, Kaneko T, Kayama N, Ueno S (2000). Effects of nilvadipine on retinal microcirculation and systemic circulation. *Nippon Ganka Gakkai Zasshi*. 104(10):699-705. Japanese.
40. Uemura A, Mizota A (2008). Retinal concentration and protective effect against retinal ischemia of nilvadipine in rats. *Eur J Ophthalmol*. 18(1):87-93.
41. Ohguro H (2008). New drug therapy for retinal degeneration. *Nippon Ganka Gakkai Zasshi*. 112(1):7-21.
42. Yamamoto T, Niwa Y, Kawakami H, Kitazawa Y (1998). The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma. *J Glaucoma*. 7(5):301-305.
43. Tomita G, Niwa Y, Shinohara H, Hayashi N, Yamamoto T, Kitazawa Y (1999). Changes in optic nerve head blood flow and retrobulbar hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma. *Int Ophthalmol*. 23(1):3-10.
44. Niwa Y, Yamamoto T, Harris A, Kagemann L, Kawakami H, Kitazawa Y (2000). Relationship between the effect of carbon dioxide inhalation or nilvadipine on orbital blood flow in normal-tension glaucoma. *J Glaucoma*. 9(3):262-267.

45. Oku H, Sugiyama T, Kojima S, Watanabe T, Ikeda T (2000). Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. *Curr Eye Res.* 20(2):101-108.
46. Karim Z, Sawada A, Kawakami H, Yamamoto T, Taniguchi T (2006). A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. *Curr Eye Res.* 31(3):273-283.
47. Tamaki Y, Araie M, Fukaya Y, Nagahara M, Imamura A, Honda M, Obata R, Tomita K (2003). Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. *Invest Ophthalmol Vis Sci.* 44(11):4864-4871.